
Polaris Rx Chosen by Bristol Myers Squibb to Distribute ZENBEXUS™, the First FDA-Approved CELMoD Treatment for Multiple Myeloma
Polaris Rx Selected by Bristol Myers Squibb to Dispense First-in-Class Multiple Myeloma Therapy ZENBEXUS (Iberdomide) Polaris Rx has announced that it has been selected by Bristol Myers Squibb (BMS) to dispense ZENBEXUS™ (iberdomide), the first cereblon E3 ligase modulator (CELMoD)…













